Self-Administered, Subcutaneous Alemtuzumab to Treat Residual Disease in Patients With Chronic Lymphocytic Leukemia

BACKGROUND: Alemtuzumab is highly effective at treating chronic lymphocytic leukemia (CLL) in bone marrow, which is the usual site of residual disease after fludarabine-based treatment. Eliminating residual disease potentially is associated with longer remission and overall survival. The authors of...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer
Главные авторы: Wierda, William G., Kipps, Thomas J., Keating, Michael J., Brown, Jennifer R., Gribben, John G., Browning, Mary, Rassenti, Laura Z., Greaves, Andrew W., Neuberg, Donna, O’Brien, Susan M.
Формат: Artigo
Язык:Inglês
Опубликовано: 2010
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4535917/
https://ncbi.nlm.nih.gov/pubmed/20806349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.25379
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы